Eversept Partners, LP Aurinia Pharmaceuticals Inc. Transaction History

Eversept Partners, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$10.05 - $22.48 $2.02 Million - $4.53 Million	-201,384 Closed	0 $0
Q4 2021 Nov 08, 2023	SELL	$17.78 - $33.08 $7.17 Million - $13.3 Million	-402,984 Reduced 66.68%	201,384 $4.61 Million
Q4 2021 Feb 14, 2022	BUY	$17.78 - $33.08 $3.58 Million - $6.66 Million	201,384 New	201,384 $4.61 Million
Q1 2021 May 13, 2021	SELL	$12.3 - $18.73 $7.43 Million - $11.3 Million	-604,368 Closed	0 $0
Q4 2020 Nov 08, 2023	BUY	$12.94 - $16.05 $7.82 Million - $9.7 Million	604,368 New	604,368 $8.36 Million
Q4 2020 Feb 16, 2021	BUY	$12.94 - $16.05 $2.18 Million - $2.7 Million	168,373 Added 38.62%	604,368 $8.36 Million
Q3 2020 Nov 08, 2023	SELL	$13.19 - $16.66 $1.48 Million - $1.87 Million	-112,330 Reduced 20.49%	435,995 $6.42 Million
Q3 2020 Nov 13, 2020	SELL	$13.19 - $16.66 $1.48 Million - $1.87 Million	-112,330 Reduced 20.49%	435,995 $6.42 Million
Q2 2020 Nov 08, 2023	BUY	$14.12 - $18.33 $7.74 Million - $10.1 Million	548,325 New	548,325 $8.91 Million
Q2 2020 Aug 13, 2020	BUY	$14.12 - $18.33 $7.74 Million - $10.1 Million	548,325 New	548,325 $8.91 Million

214

58.3M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.13B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.